Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 2/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 3/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023161 | 0.85 | HSP90AA1 (0.34) | JAK1JAK3HSP90AA1MTORPIK3CA | |
| SCHEMBL584192 | 0.85 | HSP90AA1 (0.38) | HSP90AA1MTORPIK3CANPC1RAB9A | |
| SCHEMBL29142 | 0.84 | MET (0.32) | METTTKCYP3A4 | |
| SCHEMBL584040 | 0.82 | ATR (0.41) | MTORPIK3CANPC1RAB9AMEN1 | |
| SCHEMBL1027004 | 0.81 | HSP90AA1 (0.32) | JAK1JAK3HSP90AA1PIK3CAAVPR1B | |
| SCHEMBL7879162 | 0.81 | RAB9A (0.39) | NPC1RAB9AMEN1NR2F2KMT2A | |
| SCHEMBL31339 | 0.80 | KDM4E (0.33) | PIK3CANPC1RAB9AMEN1KMT2A | |
| SCHEMBL6893755 | 0.80 | JAK1 (0.44) | JAK1JAK3HSP90AA1MTORPIK3CA | |
| SCHEMBL1027003 | 0.80 | HSP90AA1 (0.32) | JAK1JAK3HSP90AA1PIK3CAAVPR1B | |
| SCHEMBL1083466 | 0.78 | AKR1C3 (0.32) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | JAK1 1133/4885JAK3 1503/4885HSP90AA1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.